Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Sarcoma PDX Models to Advance your Sarcoma Therapies
Champions Oncology offers 136* clinically relevant Sarcoma PDX models derived from patients with late-stage, metastatic, and heavily pretreated disease, many of whom received Standard of Care therapies. Of these, 68* models have been characterized through Next Generation Sequencing (WES and RNA-seq) and in vivo drug response testing, providing a robust and diverse dataset for evaluating biomarkers of response and non-response in this indication. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Sarcoma PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Access to the largest bank of Sarcoma PDX models with clinically relevant molecular
and pathological characteristics on the market. -
Most Sarcoma models were pretreated with standard of care therapies, including ifosfamide/eptoposide or cisplatin/gemcitabine combinations, and include models resistant to targeted treatments and advanced cancer therapies.
-
Access to highly characterized Sarcoma models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.